Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy

PharmacoEconomics

Volumn 13, Issue 6, 1998, Pages 697-705

  Anis, Aslam H ^a,b,c   Hogg, Robert S ^a,c   Wang, Xiao Hua ^c   Yip, Benita ^a   Palepu, Anita ^c   Montaner, Julio S G ^a,b,c   O'Shaughnessy, Michael V ^a,b,c   Schechter, Martin T ^a,b,c  

^a ST PAUL S HOSPITAL   (Canada)

^b Canadian HIV Trials Network   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; CANADA; COMBINATION CHEMOTHERAPY; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; ECONOMIC ASPECT; FEMALE; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BRITISH COLUMBIA; COST OF ILLNESS; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, ECONOMIC;

EID: 0031834865     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813060-00006     Document Type: Article

References (26)

1. Carpenter CCJ, Fischl MA, Hammer SC, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the international AIDS society USA panel. JAMA 1997; 277 (24): 1962-9
2. Petrou S. Current controversies in the treatment of HIV infection and AIDS. Pharmacoeconomics 1996; 10 (2): 105-8
3. Schulman KA, Lynn LA, Glick HA, et al. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991; 114 (9): 798-802
4. Chancellor JV, Hill AM, Sabin A, et. al. Modeling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997; 12(1): 54-66
5. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. Pharmacoeconomics 1996; 10(2): 109-13
6. Bloom DE, Carliner G. The economic impact of AIDS in the United States. Science 1988; 239: 604-9
7. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987; 102: 5-17
8. BC Centre for Excellence in HIV/AIDS. Therapeutic guidelines for the treatment of HIV/AIDS and related conditions. Vancouver: British Columbia Centre for Excellence in HIV/AIDS. 1996
9. World Health Organization (WHO). Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 1990; 65: 221-8
10. Centers for Disease Control (CDC). Leads from the MMWR: revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. JAMA 1987; 258: 1143-54
11. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantification of HIV-RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-9
12. O'Brian WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-31
13. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70
14. Finkler SA. The distinction between cost and charge. Ann Intern Med 1982; 96: 102-9
15. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
16. Hogg RS, Montaner JSG, Sherlock C, et al. Estimating the cost of using plasma viral load determinations for staging and therapeutic monitoring of HIV disease [abstract no. Th.B.913]. The XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
17. Neave HR, Worthington PL. Distribution-free tests. London: Routledge, 1998
18. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health 1993; 14: 43-68
19. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation. Biometrics 1988; 44 (4): 1049-60
20. Anis AH, Hogg RS, Yip B, et al. Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women. Pharmacoeconomics 1998; 13 (3): 327-36
21. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. Pharmacoeconomics 1996; 10(2): 109-13
22. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunsupression in an urban HIV-infected population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 223-31
23. 3 and ≥3 months prior therapy zdv experience. 1997
24. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9
25. Hammer SM, Squires KE, Hughes MD. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
26. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81